Skip to main content

Table 5 Comparison of cellular factors levels between the groups positive and negative for HPV

From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer

Cellular Factors

PCa group (a) vs control (b)

HPV-positive samples (c) vs HPV-negative samples (d)

HPV-positive PCa (e) vs HPV-negative PCa (f)

HPV-positive control (g) vs HPV-negative control (h)

P*

P+

P$

P^

NF-κB

a:19.4 ± 7.4

b:9.5 ± 7

c: 23.5 ± 5.8

d: 13.2 ± 7.9

e: 24.2 ± 6

f: 17 ± 7

g: 20 ± 3.9

h: 8 ± 6.05

< 0.0001

< 0.0001

0.00091.42

0.004

TNF-α

a:17 ± 7.4

b:11.7 ± 6.7

c: 21.1 ± 6

d: 12.8 ± 6.6

e: 22.4 ± 6.4

f: 14.3 ± 6.4

g: 19.5 ± 3.1

h: 10.6 ± 6.3

0.002

< 0.0001

< 0.0001

1.56

0.03

IL-1

a:13 ± 5.7

b:7.8 ± 5.3

c: 17.2 ± 4.1

d: 9.1 ± 5.2

e: 17.3 ± 4.1

f: 10.9 ± 5.1

g: 16.7 ± 4.2

h: 6.5 ± 4.1

0.0002

< 0.0001

0.0003

1.57

0.002

IL-6

a:14.4 ± 6

b:8.9 ± 6.6

c: 18.9 ± 5

d: 10.2 ± 5.8

e: 18.9 ± 5.2

f: 12.2 ± 5.2

g: 19 ± 3.9

h: 7.5 ± 5.6

0.0004

< 0.0001

< 0.0001

2.51

0.0004

IL-8

a: 12.62 ± 6.2

b: 5.68 ± 5.1

c: 17.3 ± 5.1

d:7.6 ± 5.3

e: 17.7 ± 5.4

f: 10.1 ± 5.09

g: 15.5 ± 3.1

h: 4.2 ± 3.5

< 0.0001

< 0.0001

0.004

1.77

0.006

IL-11

a: 15.6 ± 8.3

b: 7.1 ± 6.2

c: 20.52 ± 6.8

d: 9.8 ± 7.4

e: 21.2 ± 7.2

f: 12.8 ± 7.4

g: 17 ± 5.08

h: 5.7 ± 4.1

< 0.0001

< 0.0001

0.02

1.6

ns

VEGF

a: 38.64 ± 10.8

b: 13.7 ± 6.9

c: 48.5 ± 9.5

d: 25.8 ± 12.5

e: 52.58 ± 3.5

f: 35.8 ± 4.2

g: 29.5 ± 1.2

h: 11.9 ± 3.7

< 0.0001

< 0.0001

0.0009

1.46

0.005

TGF-β

a: 15.2 ± 7.6

b: 7.5 ± 5.1

c: 19.2 ± 5.7

d: 10.1 ± 7

e: 19.9 ± 6.1

f: 12.9 ± 7.2

g: 16 ± 1.6

h: 6.2 ± 4.2

< 0.0001

< 0.0001

0.02

1.54

ns

Rb

a: 9.1 ± 5.7

b: 14.06 ± 6.4

c: 2.4 ± 1.08

d: 13.8 ± 4.6

e: 2.6 ± 1.01

f: 12.3 ± 4.1

g: 1.5 ± 1

h: 15.8 ± 4.6

0.0006

< 0.0001

< 0.0001

0.0003

P53

a: 10.4 ± 6.7

b: 13.9 ± 6.6

c: 3 ± 1.3

d:14.7 ± 5.2

e: 3.2 ± 1.35

f: 14.03 ± 5.2

g: 2 ± 0.8

h: 15.68 ± 5.09

0.04

< 0.0001

< 0.0001

0.002

ROS

a: 10.2 ± 9.7

b: 6.09 ± 5.3

c: 22.3 ± 5.7

d: 3.7 ± 2.7

e: 23.4 ± 5.5

f: 3.1 ± 2.04

g: 17 ± 3.6

h: 4.5 ± 3.3

0.03

< 0.0001

< 0.0001

7.5

ns

RNS

a: 11.8 ± 10.3

b: 5.2 ± 5.3

c: 19.7 ± 8.9

d: 5.9 ± 6.5

e: 20.2 ± 9.7

f: 7.7 ± 7.8

g: 17.2 ± 2.6

h: 3.5 ± 2.8

0.0002

< 0.0001

0.0004

2.6

0.003

Survivin

a: 17.8 ± 4.8

b: 9 ± 6.2

c: 22 ± 3.2

d: 12.1 ± 5.8

e: 21.9 ± 3.2

f: 15.8 ± 4.1

g: 22.7 ± 3.5

h: 7.03 ± 3.2

< 0.0001

< 0.0001

0.0006

< 0.0001

Bcl-2

a: 12.1 ± 4.2

b: 6.4 ± 4.5

c: 15.9 ± 3.4

d: 8.1 ± 3.9

e: 15.6 ± 3.7

f: 10.4 ± 3.4

g: 17.3 ± 0.8

h: 4.9 ± 1.9

0/0001

< 0.0001

0.002

< 0.0001

CD44

a: 7.9 ± 5.1

b: 4.03 ± 2.4

c: 7.8 ± 5.1

d: 6.1 ± 4.5

e:7.9 ± 5.4

f: 8 ± 5.01

g: 7.5 ± 3.8

h: 3.5 ± 1.8

0.0003

ns

ns

ns

TWIST

a: 10.2 ± 12.2

b: 6.4 ± 7.2

c: 25.7 ± 7.5

d: 3.1 ± 2.6

e: 26.2 ± 8.1

f: 2.4 ± 1.3

g: 23 ± 1.6

h: 4.03 ± 3.5

ns

< 0.0001

< 0.0001

ns

E-cad

a: 12.9 ± 8.4

b: 13.5 ± 5.6

c: 3.4 ± 2.08

d: 16.5 ± 5.6

e: 3.5 ± 2.2

f:17.5 ± 6.2

g: 3 ± 0.8

h: 15.07 ± 4.2

ns

< 0.0001

< 0.0001

< 0.0001

N-cad

a: 10.7 ± 11.6

b: 5.8 ± 8.4

c: 25.8 ± 7.6

d:3.2 ± 2.4

e: 25.7 ± 8.09

f: 3.4 ± 2.1

g: 26.2 ± 6.2

h: 2.9 ± 2.7

0.009

< 0.0001

< 0.0001

0.004

PTPN13

a: 9.7 ± 5.9

b: 12.9 ± 6.6

c: 4.4 ± 5.6

d: 13.1 ± 5

e: 5 ± 6.01

f:12.08 ± 4.4

g: 2 ± 0.8

h: 14.5 ± 5.5

0.03

< 0.0001

0.0007

0.004

SLUG

a: 2.1 ± 1.8

b: 1.1 ± 2.7

c: 3.8 ± 1.4

d: 1.01 ± 1.9

e: 3.9 ± 1.4

f: 1.2 ± 1.3

g: 3.4 ± 1.2

h: 0.6 ± 2.6

ns

< 0.0001

< 0.0001

Ns

  1. Geometric Mean ± Standard Deviation, *: comparison between group a versus group b, +: comparison between group c versus group d, $: comparison between group e versus group f, ^: $: comparison between group g versus group h, FDR correction for multiple comparisons by Benjamini-Hochberg method